Trial reportCancer immunology, immunotherapy : CII2012
An immune-active tumor microenvironment favors clinical response to ipilimumab.
Trial report in Cancer immunology, immunotherapy : CII, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 462 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
462 citing papers in PubMed, 1 synthesis or guideline pooled it, 775 citations in OpenAlex.
- Pooled it
- Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial.British journal of cancer · 2020Trial
- Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases.Cancer biology & therapy · 2020Trial
- Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer.Journal for immunotherapy of cancer · 2020Trial
- Poliosis predicts durable response to immune-checkpoint blockade in metastatic melanoma: a multicenter cohort study.Journal for immunotherapy of cancer · 2026Article
- Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma.Nature biotechnology · 2026Article
- Preclinical Characterization of CLSP-1025, a First-in-Class, Mutation-Specific T-Cell Engager Targeting a Neoantigen Derived from a Common p53 Mutation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Stiff matrix impairs cytotoxic T lymphocyte function at multiple levels.Science advances · 2026Article
- Diagnosis and Management of Sarcoidosis-like Reaction in Adjuvant Immunotherapy: A Comprehensive Review and Clinical Implications.Biomedicines · 2026Review
- Five dominant amino acid substitution signatures shape tumour immunity.Molecular systems biology · 2026Article
- Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients.Biomarker research · 2026Article
- Functionally heterogeneous intratumoral CD4Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Liposomal J-Aggregates of Indocyanine Green as a Multifunctional Contrast Agent for Photoacoustic Imaging and Photothermal Therapy.Nanotheranostics · 2026Article
- Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion.Signal transduction and targeted therapy · 2026Review
- Oncolytic virus and immunogenic cell death in cancer therapy.Tumour virus research · 2025Review
- Categorizing immunotherapy resistance mechanisms in non-small cell lung cancer: how can we perform better?Journal for immunotherapy of cancer · 2025Review
- Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor models.Journal for immunotherapy of cancer · 2025Article
- Artificial intelligence-based digital pathology using H&E-stained whole slide images in immuno-oncology: from immune biomarker detection to immunotherapy response prediction.Journal for immunotherapy of cancer · 2025Review
- Tumor Cell-Intrinsic Decr2 Regulates Ferroptosis and Immunotherapy Efficacy.Cancer immunology research · 2025Article
- Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2025Article
402 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIpilimumab, a fully human monoclonal antibody specific to CTLA-4, has been shown to improve overall survival in metastatic melanoma patients. As a consequence of CTLA-4 blockade, ipilimumab treatment is associated with proliferation and activation of peripheral T cells. To better understand various tumor-associated components that may influence the clinical outcome of ipilimumab treatment, gene expression profiles of tumors from patients treated with ipilimumab were characterized. EXPERIMENTAL
designGene expression profiling was performed on tumor biopsies collected from 45 melanoma patients before and 3 weeks after the start of treatment in a phase II clinical trial.
resultsAnalysis of pre-treatment tumors indicated that patients with high baseline expression levels of immune-related genes were more likely to respond favorably to ipilimumab. Furthermore, ipilimumab appeared to induce two major changes in tumors from patients who exhibited clinical activity: genes involved in immune response showed increased expression, whereas expression of genes for melanoma-specific antigens and genes involved in cell proliferation decreased. These changes were associated with the total lymphocyte infiltrate in tumors, and there was a suggestion of association with prolonged overall survival in these patients. Many IFN-γ-inducible genes and Th1-associated markers showed increased expression after ipilimumab treatment, suggesting an accumulation of this particular type of T cell at the tumor sites, which might play an important role in mediating the antitumor activity of ipilimumab.
conclusionsThese results support the proposed mechanism of action of ipilimumab, suggesting that cell-mediated immune responses play an important role in the antitumor activity of ipilimumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.